|
Source
Cancer 2005;104(2):236-9. Abstract
Background
As second-line therapy, fulvestrant was as effective as anastrozole in terms of
time to disease progression and objective response rates.
Methods
A prospectively planned, combined, overall survival analysis was performed on
data from two Phase III trials that compared fulvestrant (250 mg monthly;
n = 428) with anastrozole (1 mg daily; n = 423) in the treatment of postmenopausal
women with advanced breast carcinoma who had disease progression
after receipt of previous endocrine treatment.
Results
- Prolonged survival was observed with both drugs, with 10 to 20 percent of
patients still alive >5 years after randomization.
- Median overall survival was 27.4 months and 27.7 months in fulvestrant and
anastrozole-treated patients, respectively (hazard ratio, 0.98; p = 0.809).
SELECT PUBLICATIONS
Bundred NJ et al. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover
index more effectively than tamoxifen. Anticancer Res 2002;22(4):2317-9. Abstract
Carlson RW. The history and mechanism of action of fulvestrant. Clin Breast Cancer 2005;6(Suppl 1):5-8. Abstract
Dodwell D, Vergote I. A comparison of fulvestrant and the third-generation aromatase
inhibitors in the second-line treatment of postmenopausal women with advanced breast
cancer. Cancer Treat Rev 2005;31(4):274-82. Abstract
Franco S et al. Response to fulvestrant in heavily pretreated postmenopausal women: A
single-center experience. Breast Cancer Res Treat 2004;88(2):103-8. Abstract
Howell A. The future of fulvestrant (“Faslodex”). Cancer Treat Rev 2005;31(Suppl 2):26-33.
Abstract
Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of
advanced breast cancer in postmenopausal women previously untreated with endocrine
therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13.
Abstract
Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in
postmenopausal women with advanced breast cancer progressing after prior endocrine
treatment. J Clin Oncol 2002;20(16):3396-403. Abstract
Johnston SR et al. Life following aromatase inhibitors — Where now for endocrine
sequencing? Breast Cancer Res Treat 2005;93(Suppl 1):19-25. Abstract
Jones SE, Pippen J. Effectiveness and tolerability of fulvestrant in postmenopausal women
with hormone receptor-positive breast cancer. Clin Breast Cancer 2005;6(Suppl 1):9-14.
Abstract
Mauriac L et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment
of advanced breast cancer in subgroups of postmenopausal women with visceral and
non-visceral metastases: Combined results from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract
Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability
of fulvestrant versus anastrozole in postmenopausal women with advanced breast
cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract
Robertson JF et al. Sensitivity to further endocrine therapy is retained following progression
on first-line fulvestrant. Breast Cancer Res Treat 2005;92(2):169-74. Abstract
Vergote I et al; Trial 0020 Investigators; Trial 0021 Investigators. Postmenopausal women who
progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79(2):207-11. Abstract
|
